This research was done entirely in mice, not in people. That limit needs to be clear from the start. Around a billion heart muscle cells can die in the minutes and hours after a single heart attack. The heart does not replace them. That lasting loss is a major reason many people later slip into heart failure. No approved medicine has been able to bring those lost cells back.
Researchers at the University of Cambridge may have found a way to help the heart repair itself, at least in mice. The findings were published in Nature Cardiovascular Research on November 9, 2026. No human trials have taken place, and this is not a treatment doctors can offer patients. What the team showed in the lab is a new way of asking the adult heart to mend itself.
The idea is almost the opposite of a transplant or a drug that only slows more damage. The Cambridge team used an mRNA therapy, the same general technology behind COVID-19 vaccines, to briefly wake up the heart’s own muscle cells and push them to divide. Adult heart muscle cells have almost entirely lost that ability. Getting them to restart it, even for a short time, is a goal researchers have chased for decades.
Why can’t the heart heal itself after a heart attack?
In a large heart attack, the sudden loss of up to a billion cardiomyocytes, or heart muscle cells, is more than the adult heart can replace. The heart fills the gap with a fibrotic scar, which is a patch of tough tissue, instead of making new muscle. The damage is then effectively permanent.
This is not so much a failure of today’s medicines as a feature of how the adult heart grows. Early in life, heart muscle cells can still divide. By adulthood, that switch is almost entirely off. The cells are still alive. They just will not multiply.
As the Cambridge paper notes, Myc and cyclin T1 can drive cells to divide. But if those proteins stay turned on all through the heart, heart function can get worse. That is the core tension. The signals that might trigger repair can also cause dangerous overgrowth if they stay on too long.
Earlier experiments showed that turning on Myc and cyclin T1 broadly throughout the heart could cause severe toxicity. The researchers also found that Myc alone was not enough to make adult heart muscle cells divide. Those cells have low levels of P-TEFb, a protein complex that contains CDK9 and cyclin T1. The Cambridge team’s answer was precise and short-lived. They used modified mRNA to deliver a brief, local pulse of both proteins together, then let the therapy fade on its own.
Around 200,000 people in the United Kingdom are diagnosed with heart failure each year. Current treatments can ease symptoms and slow the disease. They cannot rebuild heart muscle that has already been lost. For anyone living with the later effects of heart disease, that gap is the reason this mouse work is getting attention.
Read More: Heart Failure Could Be Reversed as the Human Heart May Have Self-Healing Abilities
How does the mRNA heart therapy work?
The study used modified mRNA that codes for two proteins, Myc and cyclin T1, to briefly turn on cell division in adult heart muscle. Myc helps switch on cell growth. Cyclin T1, part of the P-TEFb complex, helps keep that process running. Neither protein is unusual in biology. Both play normal roles in developing cells. The hard part has always been turning them on in the right place, at the right time, without letting them run unchecked.
The mRNA is modified to make it more stable inside cells and easier to read. It is still short-lived by nature. Because the therapy does not permanently change the genome, which is the cell’s DNA instruction book, it avoids some of the risks of uncontrolled cell growth. The proteins rise briefly, nudge heart muscle cells into dividing, and then the mRNA breaks down on its own. No lasting genetic change is left behind.
In the study, mice that had a heart attack were given an injection of the mRNA therapy directly into the heart. The researchers then used an echocardiogram, the same kind of ultrasound used in a clinic, to measure how well the heart was pumping. The brief pulse of Myc and Cyclin T1 promoted heart muscle cell division. It increased the amount of blood pumped with each beat by about 10% compared with a mock treatment.
What did the mouse data show?
A 10% gain in blood pumped per beat matters in the setting of heart failure. Even small improvements in heart function have been linked, in people, to lower death rates and a better ability to do daily activities. Those human links come from other research. They do not prove this mouse treatment will do the same in patients. For someone whose heart already struggles to supply the body with blood, a 10% gain in pumping capacity could, in theory, be the difference between being stuck at home and climbing a flight of stairs.
Ejection fraction, or EF, is the share of blood pumped out of the heart’s main chamber with each beat. That number tells a similar story. In mice given the Myc and cyclin T1 modified mRNA right after an experimentally induced heart attack, left ventricular ejection fraction fell by 26% after 28 days. In control-treated mice, it fell by 37%. Both groups still lost some function, because a heart attack had occurred. The treated mice held on to more of their pumping ability.
When the mice were checked again after 28 days and after 12 weeks, the gain in heart function was still there. A therapy that spiked and then faded would be of limited use. The benefit lasting at 12 weeks, well after the mRNA itself was gone, suggests the new cells made during that brief window were settling into the heart and helping it work over time.
No harmful effects were seen in mice that received the mRNA treatment. The local, short-lived design appears to be a big part of that safety picture. Because the mRNA breaks down quickly and the protein pulse is brief, the cells do not keep dividing without end. That kind of ongoing growth is the main worry with any plan that turns growth signals back on in tissue.
Who led the research?
Dr. Catherine Wilson is an associate professor at the University of Cambridge’s Department of Pharmacology and the Gurdon Institute. She is a co-senior author of the study. Her lab has worked toward this approach for years, aiming at a therapy that does more than manage heart failure symptoms and instead addresses the missing cells.
“We’re not just treating the symptoms of heart failure,” she said. “This approach could help the heart to repair itself.”
The work was a collaboration between the University of Cambridge, QIMR Berghofer Medical Research Institute, and AstraZeneca. The results were published on November 9, 2026, in the peer-reviewed journal Nature Cardiovascular Research.
What still has to happen before this could reach patients?
The Cambridge team is careful not to overstate where this research stands. The study used short-lived mRNA to drive heart muscle cell division and improve heart function, but only in mice. Mouse hearts differ from human hearts in important ways, including heart rate, cell size, and how fast the heart remodels after injury. Results that hold in mice do not always transfer to larger animals, let alone people.
According to the University of Cambridge, further trials in larger animal models and then in humans are needed to fully establish safety and effectiveness. That path typically takes years, often a decade or more, from this kind of early proof to an approved treatment. No harmful effects were seen in these local mRNA experiments. That is not proof of long-term safety. Only larger and more careful trials can show that.
The therapy might one day be used to treat people with heart failure, but the research is still at an early stage. The team has funding from the British Heart Foundation. It is now focused on refining delivery, timing, and dose before moving into larger animals.
Injecting mRNA directly into the heart, as was done in mice, is a high bar for human care. Better delivery methods would likely be needed before any clinical trial. No timeline for human testing has been announced.
What does this mean for you?
This research does not change what is available at a cardiologist’s office today. No mRNA heart therapy is approved, in human trials, or expected to reach patients soon. Anyone managing heart failure or recovering from a heart attack should keep working with their medical team and follow their current treatment plan.
The Cambridge study shows that, in mice, heart muscle cells can be nudged back into division under controlled conditions, and that the benefit can last. No approved therapy can currently replace heart muscle that has already been lost. This work adds early lab evidence that fixing that deficit at the cell level may be possible. The path to any use in people remains long and uncertain.
Do not stop, start, or change any heart medicine because of this research. Talk with your doctor about your own care and about any new symptoms. This mouse study is a promising lead. It is not a reason to wait for a future therapy instead of using the care that already helps people survive a heart attack and live with heart failure.
Editor’s note: The headline describes an mRNA therapy that reawakens heart muscle cells to repair damage. The University of Cambridge findings come from mice only. The treatment is not available for people, and larger animal studies and human trials are still needed.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.